Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Pricing Rules for Innovative Drugs Will Not Be a Priority in Discussions by Regulatory Reform Council
March 12, 2013
- PAFSC’s First Committee Recommends Approval for OAB Drug Neoxy Tape
March 11, 2013
- Health Sciences Council to Discuss Protocol for Clinical Trial Using iPS Cells
March 11, 2013
- Kyoto Medical Association Vice President Hideki Adachi Says Drug Makers Should Closely Verify NHI Prices and Development Costs of Each Drug
March 8, 2013
- Drug Safety Monitoring Program of RMPs to Be Announced via PMDA’s Website: PFSB Notification
March 7, 2013
- Over 40% of Preliminary Meetings Proceed to Face-to-Face Consultation Meetings in Regulatory Strategy Consultation Services: Report
March 7, 2013
- MHLW to Announce Revised GVP, GPSP Ordinances “Early Next Week”: Director Tawaragi of PFSB
March 6, 2013
- MHLW Approves 45 New Compounds in 2012: Mr Akagawa of PFSB
March 6, 2013
- MHLW Aims to Submit Bill to Amend PAL During Current Diet Session: PFSB Director-General Jun Ebata
March 6, 2013
- PAFSC Second Committee to Discuss Pfizer’s Xeljanz and Bayer’s Stivarga on March 13
March 5, 2013
- PAFSC First Committee on New Drugs to Discuss Approval of New Parkinson’s Disease Agent and DPP-4 Inhibitor Onglyza
March 5, 2013
- Health and Education Ministries along with Drug Makers to Start Intractable Disease Research using iPS Cells
March 5, 2013
- Lawmakers Organizing Non-Partisan Group to Break Deadlock on Establishment of 3rd-Party Drug Administration Watchdog Organization
March 5, 2013
- Generic Share by Volume Rose to 28.7% in September 2012, MHLW Reports
March 4, 2013
- Tokyo District Court Dismisses Takeda’s Actos Litigation Against 10 Companies; No Appeal Planned
March 4, 2013
- Japan’s Average Drug Price is 1.44 Times Higher than Europe: MHLW Tally
March 1, 2013
- MHLW’s Health and Medical Strategy HQ Aims to Draft a Final Plan by May
February 28, 2013
- Pharmacies’ Generic Drug Dispensing Rate Rises to 29.4%: Survey Reported to CSIMC
February 28, 2013
- 5 Years Too Long to Achieve Reference Generic Share Target of 60%: Bill Payer Reps at CSIMC Subcommittee
February 28, 2013
- Shuji Shirakawa of Kenporen Says Long-Listed Product Price Cuts Irrelevant to New Drug Development Premium
February 28, 2013
ページ
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…